Accurate detection and quantification of hepatitis delta virus (HDV) RNA are essential for diagnosis, prognosis and treatment monitoring. This study aimed to evaluate whether thermal shock ...
Hepatitis delta virus (HDV), a bloodborne infection that is transmitted through infected blood or other bodily fluids, was recently designated as a Group 1 carcinogen by the International Agency for ...
CEO Marianne De Backer emphasized Vir's progress in advancing its infectious disease and oncology programs. Key milestones include initiating the ECLIPSE Phase III registrational program for hepatitis ...
THURSDAY, June 4, 2026 (HealthDay News) -- The U.S. Food and Drug Administration has approved Hepcludex (bulevirtide-gmod) injection to treat chronic hepatitis delta virus (HDV) infection in adults ...
– Phase 3 primary endpoint (virologic response and ALT normalization) achieved in both dose arms at Week 24 – 48-week data from Phase 2b portion of AZURE-1 demonstrate deepening viral suppression and ...
Mirum Pharmaceuticals’ phase 3 AZURE-1 study of brelovitug in chronic hepatitis delta virus meets primary endpoint: Foster City, California Tuesday, September 29, 2026, 15:00 Hr ...
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced the primary endpoint was met in the Phase 3 portion of the AZURE-1 study evaluating brelovitug, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results